Response to "Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients", by L. Morales et al. (Ann Oncol 2005; 16: 70–74)

I read with great interest the article by Morales et al. [1Go], describing a potential reversal of tamoxifen-induced uterine changes, by third-generation aromatase inhibitors. The authors found that aromatase inhibitors can decrease endometrial thickness (and uterine volume) in patients previously treated with tamoxifen for 3 months.

However, it may well be that the decrement of endometrial thickness was mainly due to discontinuation of tamoxifen treatment, regardless of the administration of aromatase inhibitors, as it has been shown that endometrial thickness is significantly reduced within 6 months following tamoxifen discontinuation, and remains constantly low thereafter [2Go, 3Go].

A second issue is the endometrial pathologies identified in the tamoxifen-treated patients; the authors mentioned that endometrial polyps were identified in some of these patients, exclusively diagnosed by transvaginal ultrasonography [1Go]. However, it is usually impossible to distinguish between endometrial polyps and subendometrial fibroids without their direct visualization through hysteroscopy. Thus, the shrinkage of these polyps may well be a decrease in size of subendometrial fibroids rather than that of a polypoid tissue.

I. Cohen

Department of Obstetrics and Gynecology, Meir Hospital-Sapir Medical Center, Kfar-Saba, Israel (E-mail: bensonm{at}clalit.org.il)

References

1. Morales L, Timmerman D, Neven P et al. Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients. Ann Oncol 2005; 16: 70–74.[Abstract/Free Full Text]

2. Cohen I, Beyth Y, Azaria R et al. Ultrasonographic measurement of endometrial changes following discontinuation of tamoxifen treatment in postmenopausal breast cancer patients. Br J Obstet Gynecol 2000; 107: 1083–1087.[ISI]

3. Gerber B, Krause A, Muller H et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: A prospective long-term study using tranvaginal ultrasound. J Clin Oncol 2000; 18: 3464–3470.[Abstract/Free Full Text]





This Article
Full Text (PDF)
All Versions of this Article:
16/8/1402    most recent
mdi236v1
E-letters: Submit a response
Alert me when this article is cited
Alert me when E-letters are posted
Alert me if a correction is posted
Services
Email this article to a friend
Similar articles in this journal
Similar articles in ISI Web of Science
Similar articles in PubMed
Alert me to new issues of the journal
Add to My Personal Archive
Download to citation manager
Disclaimer
Request Permissions
Google Scholar
Articles by Cohen, I.
PubMed
PubMed Citation
Articles by Cohen, I.